Stockscreener 앱 받기
15.34
0.52%
-0.08
시간 외 거래:
15.34
Takeda Pharmaceutical Co Adr 주식(TAK)의 최신 뉴스
Nano Dimension Ltd ADR’s Shares Reel: -28.07% Quarterly Revenue Decline Amid 329.06M Market Cap - investchronicle.com
MNST’s Stock Market Adventure: 19.08% YTD Growth Amidst Volatility - investchronicle.com
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
IgA nephropathy Pipeline Drugs Analysis 2025: Clinical Trials, - openPR.com
Takeda files executive compensation report with SEC - Investing.com
Cameco Earns Relative Strength Rating Upgrade; Hits Key Threshold - inkl
Stocks With Rising Relative Strength: Novartis ADR - inkl
Fidelity Natl Info Svcs Shows Rising Relative Strength; Still Shy Of Key Benchmark - inkl
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus - Wiley Online Library
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX
Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX
Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
Takeda continues stock plan for management in 2025 - Investing.com
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com
Takeda Pharmaceutical Co ADR [TAK] Insider Activity: An Update for Investors - knoxdaily.com
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - Yahoo Finance
A significant driver of top-line growth: Takeda Pharmaceutical Co ADR (TAK) - Sete News
Nothing is Better Than C.H. Robinson Worldwide, Inc (CHRW) stock at the moment - Sete News
Takeda Pharmaceutical Co ADR Inc. (TAK) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Carmax Inc: Analyzing KMX Stock Trends - investchronicle.com
Klaviyo Inc (KVYO) Stock: The Story of a 52-Week Stock Range - investchronicle.com
You might want to take a look at Denison Mines Corp (DNN) now - Sete News
A Look at Cousins Properties Inc (CUZ) Shares in the Recent Past Indicates Growth - Sete News
A better buy-in window may exist right now for Cheesecake Factory Inc (CAKE) - Sete News
Stocks of CN Energy Group Inc (CNEY) are poised to climb above their peers - Sete News
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - knoxdaily.com
Cintas Corporation [CTAS] Insider Activity: An Update for Investors - knoxdaily.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance
Organon expands board with new director from Takeda - Investing.com
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN
Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize
Morgan Stanley lifts Takeda stock rating, raises target to JPY5,500 - Investing.com
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo
PD Stock on the Rise: A Promising Investment - The InvestChronicle
Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
Charles Schwab Trying To Close In On Key Technical Measure - Inkl
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
0.10%
0.06%
자본화:
|
볼륨(24시간):